Issue 148 • November 2024

Cell and gene therapy approvals drive paradigm change in manufacturing

Trends in gene therapy approvals in recent years are rapidly shaping the future of manufacturing capabilities in the pharmaceutical industry.

Briefing

Pfizer to withdraw sickle cell treatment OXBRYTA from market

Feature

After the Lykos debacle, what’s next for psychedelic therapies?

Analyst Comment

Keytruda and Opdivo: a decade review

In Data

Leading innovators in aircraft air conditioning

Thematic Take

AI in the healthcare sector

Go to article: Home | Cell and gene therapy approvals drive paradigm change in manufacturingGo to article: Editor's letterGo to article: ContentsGo to article: Mimotopes Company InsightGo to article: MimotopesGo to article: Syngene Company InsightGo to article: SyngeneGo to article: BriefingGo to article: News in NumbersGo to article: Latest NewsGo to article: Latest DealsGo to article: Project UpdatesGo to article: PCI Pharma ServicesGo to article: AlfatestLAB - CPHIGo to article: RHEACELL Company InsightGo to article: In DepthGo to article: Cell and gene therapy approvals drive paradigm change in manufacturingGo to article: After the Lykos debacle, what’s next for psychedelic therapies?Go to article: Compounding pharmacies caught in counterfeit controversyGo to article: How the Covid-19 pandemic will help researchers with the mpox emergencyGo to article: Iterum’s oral sulopenem acceptance hinges on antibiotic stewardship effortsGo to article: Clinical research in the UK must build on industry collaboration, says NIHR directorGo to article: Keytruda and Opdivo: a decade reviewGo to article: Alphial - CPHIGo to article: RephineGo to article: Rephine - CPHIGo to article: Thematic Take: AIGo to article: Thematic Take: contentsGo to article: Foreword: Generative AI as a force of creative destructionGo to article: The road to advanced AI capabilitiesGo to article: AI technology: Market size and growth forecasts Go to article: Timeline: a history of AIGo to article: The impact of AI on the pharma sectorGo to article: Case studies: AI in pharmaGo to article: Latest news: AI in pharmaGo to article: AI boom set to revolutionise healthcare in EuropeGo to article: How NVIDIA grew with the healthcare market instead of pushing into itGo to article: Capturing the genAI boom for drug developmentGo to article: New AI model boosts early osteoporosis diagnosis for ageing populationsGo to article: Impact of AI on metabolic disorder clinical trialsGo to article: Resist temptation to rapidly roll out AI – executives must focus on talent and trainingGo to article: Is AI really helping employees?Go to article: Is your business ready for the rise of AI agents?Go to article: Deal activity related to AI in the pharma industry since 2021Go to article: Sponsored SupplementsGo to article: BEA TechnologiesGo to article: Techniconsult Firenze - CPHIGo to article: Science4TechGo to article: ListingsGo to article: EventsGo to article: Excellence AwardsGo to article: Innovation RankingsGo to article: Buyer's GuidesGo to article: Next issue